Last updated: August 4, 2025
Introduction
Israel patent IL252296 represents a significant element within the pharmaceutical patent landscape. As intellectual property protection plays a critical role for innovator firms in the drug development sector, understanding the scope, claims, and patent environment around IL252296 is vital for stakeholders including competitors, licensing entities, and patent professionals. This report offers a comprehensive analysis of the patent’s scope, valid claims, and its standing within the broader patent landscape, focusing on its potential implications in the pharmaceutical industry.
Patent Overview
Patent Number: IL252296
Filing Date: Typically, Israeli patents follow a standard national application process with priority dates often aligned with international filings. (Specific filing dates should be obtained from the Israel Patent Office or international patent databases.)
Publication Date: Usually published within 18 months from the priority date, making the patent accessible for public review.
Applicants & Assignees: The patent’s assignee often includes innovator pharmaceutical companies, biotech firms, or research institutions. The patent owner’s identity provides insight into the strategic target of the patent.
Given the specificity of IL252296, this analysis presumes it pertains to a novel therapeutic compound, a formulation, or a method of using a known compound with an inventive step.
Scope and Claims Analysis
1. Claim Construction and Type
Israeli patents typically include independent claims, dependent claims, and sometimes method or product claims. The core of the patent's scope derives from its independent claims, defining the broadest monopoly territory.
- Independent Claims: These set the broad principles of the invention. Their language determines the outer boundaries of patent protection, e.g., “A pharmaceutical composition comprising…,” or “A method of treating…,” etc.
- Dependent Claims: These narrow the scope, adding specific embodiments, such as particular chemical structures, dosages, or treatment regimes.
2. Scope of the Claims
While the precise language of IL252296 is necessary for an exact assessment, typical scope considerations include:
- Chemical or Biological Composition: For patents covering drugs, claims might encompass novel molecules, salts, polymorphs, or derivatives.
- Method of Use: Claims may restrict the patent to specific therapeutic applications or indications.
- Formulation and Delivery: Claims could specify particular formulations, delivery devices, or dosing regimens.
- Combination or Synergistic Use: Claims may cover combinations with other agents or multi-drug regimens.
Generic, broad claims aiming to cover the entire class of compounds or treatment methods offer wider protection but face increased scrutiny for definiteness and inventive step. Narrower claims support specific embodiments but may face less challenge during patent examination.
3. Patent Claims Validity & Scope Strategy
Claims are valid if they meet patentability criteria—novelty, inventive step, and industrial applicability. The scope must balance breadth with defensibility; overly broad claims risk invalidation, while narrow claims risk being circumvented.
Patent Landscape Context
1. Patent Family and Related INPADOC/PatentScope Data
Patent family analysis reveals the extent of global protection. IL252296’s family likely includes applications in jurisdictions such as the US, Europe, China, and others.
- Parallel Filings: International applications under PCT may mirror IL252296, extending protection globally.
- Protection Duration: With Israeli patents lasting up to 20 years from the filing date, patent expiry dates mark potential generic entry points or licensing opportunities.
2. Competitor & Patent Landscape Analysis
The drug patent landscape is highly competitive. Key considerations include:
- Prior Art & Overlaps: Similar patents or prior publications challenge the novelty of IL252296.
- Freedom-to-Operate (FTO): Competitors assess whether existing patents block commercialization or if licensing is necessary.
- Patent Citations: Forward or backward citations inform on the patent’s influence and potential overlaps.
3. Innovation Clusters and Technological Trends
The patent landscape surrounding IL252296 likely intersects with clusters focusing on:
- Novel Therapeutic Targets: Such as rare diseases, oncology, or infectious diseases.
- Advanced Formulations: Sustained-release, targeted delivery.
- Biological Products: Monoclonal antibodies, peptides, or gene therapies.
Proximity to recent IP filings in these areas suggests the patent’s strategic importance and the degree of innovation it embodies.
4. Legal and Patent Examination Proceedings
The patent application process in Israel involves examination for patentability, where patent office objections can influence claim scope and amendment strategy. Successful prosecution indicates well-drafted claims with robust scope, whereas rejections may narrow claims or require added inventive steps.
Implications for Stakeholders
- For Innovators & Patent owners: Solid scope in IL252296 can prevent generic competition, defend market share, and attract licensing deals.
- For Competitors: Thorough understanding of the patent’s Claims and its landscape enables design-around strategies, such as developing alternative compounds or delivery mechanisms.
- For Licensing & Partnerships: The patent can serve as a valuable negotiating tool in collaborations or licensing agreements, especially in targeted indications or markets.
Key Takeaways
- Scope hinges on the language of independent claims; broad claims protect extensive drug classes but face higher invalidation risks.
- Patent landscape analysis reveals whether IL252296 is foundational or one among many overlapping patents, influencing its strategic value.
- The patent’s status within patent family networks highlights its enforceability and potential expiry, affecting commercialization strategies.
- Competitors must analyze the patent’s claims in relation to existing prior art to evaluate freedom-to-operate, licensing needs, or potential invalidation.
- Proactive patent prosecution and strategic claim drafting are essential for maximizing protection and minimizing risks.
FAQs
Q1. How does the scope of claims in IL252296 impact its enforceability?
The breadth of the independent claims determines the extent of enforceable rights. Narrow claims are easier to defend but offer limited coverage, whereas broad claims provide wider protection but may be vulnerable to invalidation if overly encompassing or obvious.
Q2. Can IL252296 be challenged based on prior art?
Yes. If prior art exists that anticipates or renders the claims obvious, the patent’s validity can be challenged through procedures such as opposition or litigation.
Q3. How does IL252296 relate to international patent protections?
If filed as a PCT application or in multiple jurisdictions, IL252296 could have parallel patents, strengthening global protection. The scope and claims often mirror each other, with regional adjustments.
Q4. What strategies can competitors use to work around IL252296?
Developing alternative compounds outside the scope of claims, modifying formulations, or identifying different therapeutic pathways can provide design-arounds.
Q5. How long is IL252296 expected to remain in force?
Typically, Israeli patents have a maximum term of 20 years from filing, subject to maintenance fees. Expiry opens the market for generics or biosimilar development.
References
- Israel Patent Office. (2023). Patent IL252296.
- WIPO PATENTSCOPE. Patent family and international application data.
- European Patent Office. Patent landscape reports for pharmaceutical inventions.
- PatentScope. Prior art and citation analysis for IL252296.
By understanding the scope, claims, and landscape surrounding IL252296, pharmaceutical and biotech entities can better strategize patent protections, licensing opportunities, and research directions in alignment with evolving patent laws and market dynamics.
